Ipamorelin vs CJC-1295 No DAC: Complementary Mechanisms in GH Secretagogue Research

For laboratory research use only. Not for human or veterinary use. Not a medicinal product.

What Are Ipamorelin and CJC-1295 No DAC?

Ipamorelin (research grade) is a synthetic pentapeptide classified as a selective ghrelin mimetic, targeting the growth hormone secretagogue receptor 1a (GHS-R1a). CJC-1295 No DAC (research grade) is a modified GHRH (growth hormone-releasing hormone) analogue that binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Together, these two compounds represent the principal receptor families through which endogenous pulsatile GH release is regulated, making their comparison a priority area for peptide researchers studying the hypothalamic–pituitary axis in animal models.

Both peptides are available for in vitro research and laboratory use only. Neither has received regulatory approval for human or veterinary use by the MHRA, FDA, EMA, or any other authority.

What Are the Mechanistic Differences Between Ipamorelin and CJC-1295 No DAC?

The core mechanistic distinction lies in receptor target and intracellular signalling cascade. Ipamorelin engages GHS-R1a via Gq-protein coupling, activating phospholipase C and mobilising intracellular calcium stores within somatotroph cells. CJC-1295 No DAC, by contrast, activates GHRHR through Gs-protein coupling, elevating cyclic AMP (cAMP) and activating protein kinase A.

These two pathways are not redundant; preclinical data from rodent pituitary cell preparations suggest that Gq and Gs signalling interact synergistically at the level of somatotroph exocytosis [VERIFY]. Because each molecule targets a structurally distinct receptor with a different intracellular effector, researchers can use the pair to dissect the contribution of each axis independently — or, in experimental designs that apply both simultaneously, to probe interaction effects at the pituitary level. The Ipamorelin — Evidence Dossier provides a curated catalogue of mechanistic publications for researchers planning such studies.

How Does the 'No DAC' Modification Shape Preclinical Pharmacokinetics?

The temporal profile of receptor engagement is a key variable in GH secretagogue research. The 'No DAC' designation indicates the absence of a Drug Affinity Complex — specifically, a lysine-maleimidopropionic acid conjugate that enables covalent binding to circulating albumin in the DAC variant. Without this moiety, CJC-1295 No DAC has a substantially shorter plasma half-life in rodent models (estimated at approximately 30 minutes) [VERIFY], producing a pulsatile pattern of GHRHR activation that more closely mirrors endogenous GHRH bursts.

Ipamorelin's plasma half-life in rat models is reported at approximately two hours [VERIFY], intermediate between the No DAC variant and its DAC-bearing counterpart. For researchers designing experiments that require a specific temporal window of receptor occupancy, this pharmacokinetic distinction is methodologically significant. The comparison is explored further in the related review of Ipamorelin Selectivity in Growth Hormone Secretion: What the Preclinical Record Shows.

What Does the Preclinical Selectivity Data Show for Ipamorelin?

Ipamorelin's selectivity profile is one of its most-cited research characteristics. Unlike earlier-generation secretagogues such as GHRP-6 or GHRP-2, Ipamorelin exhibited a markedly narrower endocrine footprint in swine studies conducted by Raun et al. (1998) [VERIFY]. At equivalent molar concentrations, Ipamorelin produced measurable somatotroph responses with minimal detectable effects on ACTH, cortisol, or prolactin axes — a selectivity not observed with GHRP-6 in the same model system.

This selectivity makes Ipamorelin a preferred tool compound for researchers who need to interrogate GHS-R1a-mediated pathways without confounding hormonal co-activation. For a detailed breakdown of the selectivity evidence, researchers should consult the Ipamorelin — Evidence Dossier.

What Does the Preclinical Evidence Show for CJC-1295 No DAC?

CJC-1295 No DAC has been characterised primarily through its action on GHRHR in rodent pituitary preparations and whole-animal models. Studies in rat models have used the No DAC form to examine pulsatile somatotroph responses, with investigators measuring GH pulse amplitude and frequency as primary endpoints. Because GHRHR activation via Gs/cAMP/PKA is the canonical pathway for GHRH-mediated secretion, CJC-1295 No DAC serves as a reference GHRH analogue in mechanistic studies where researchers wish to avoid the prolonged pharmacokinetics of the albumin-binding DAC form.

Importantly, the absence of a DAC moiety does not eliminate all enzymatic lability; like native GHRH, the No DAC variant remains susceptible to dipeptidyl peptidase IV (DPP-IV) cleavage at the N-terminus, which researchers factor into their in vitro stability assessments. A broader overview of CJC-1295 evidence is available in the CJC-1295 — Evidence Dossier.

Comparison of Key Preclinical Research Parameters

The table below summarises published and inferred parameters for researchers selecting between these compounds for specific experimental designs. All values are from animal models or in vitro systems and are not validated for human use.

How Do the Two Receptor Systems Interact in Animal Models?

In vivo animal studies suggest that GHS-R1a and GHRHR signalling may exhibit convergent and potentially additive effects at the level of somatotroph exocytosis. Several rodent studies have applied simultaneous GHRH and ghrelin agonism to investigate whether the combined receptor engagement generates a GH pulse that exceeds either signal alone [VERIFY]. This interaction is thought to arise from independent second-messenger amplification — cAMP from Gs and Ca²⁺ from Gq — that together exceed the threshold for maximal vesicular release.

For researchers interested in this synergy question, a two-compound in vitro design using Ipamorelin and CJC-1295 No DAC at defined molar ratios provides a controlled methodology for separating receptor contributions from downstream amplification effects. This type of mechanistic dissection is precisely the research context for which both compounds are made available as research-grade peptides.

Absence of Human Safety Data

No peer-reviewed, controlled human safety data are available for either Ipamorelin or CJC-1295 No DAC. Anecdotal reports from non-research contexts exist online, but these lack the controlled conditions, validated assay methods, and ethical oversight required for scientific evaluation. Researchers should note that preclinical pharmacokinetic or pharmacodynamic values derived from rodent or swine models are not validated predictors of human responses.

The Ipamorelin — Evidence Dossier does not include human trial data because none meeting minimum scientific standards have been published for these specific compounds. Researchers should design studies accordingly and ensure appropriate institutional oversight for any in vivo animal work.

No Established Human Protocols

No validated human protocols — including concentration ranges, timing schedules, or combination parameters — exist for either Ipamorelin or CJC-1295 No DAC. Values derived from preclinical animal models have not been extrapolated to human contexts in any peer-reviewed regulatory submission known at the time of writing. Researchers should not apply animal-model parameters to human subjects. All experimental work should be conducted under applicable institutional, ethical, and legal frameworks.

For context on how enforcement authorities view non-research use of these peptides, the article Multiple Athletes Face Doping Bans for Ipamorelin Use documents cases in which the compound was detected in competitive sport, underlining why its classification as a research-only material is taken seriously by regulatory and anti-doping bodies.

Regulatory and Legal Status in the UK

Neither Ipamorelin nor CJC-1295 No DAC holds a marketing authorisation from the MHRA or any equivalent body. They are not listed as controlled substances under the Misuse of Drugs Act 1971, nor are they scheduled under the Psychoactive Substances Act 2016 (which exempts compounds not designed to produce psychoactive effects). However, the legal landscape for research peptides is subject to ongoing regulatory review, and researchers are advised to consult current MHRA guidance and their institution's legal team before procuring or working with these compounds.

Grey-market distribution of these peptides for human use — including online sales to end consumers without appropriate research context — is a recognised concern that has prompted regulatory scrutiny across multiple jurisdictions. Nexyra Lab supplies these compounds exclusively to qualified researchers under a research-use-only framework.

Peptide Handling in Laboratory Settings

Researchers working with lyophilised peptides such as Ipamorelin and CJC-1295 No DAC in laboratory settings should follow established SOPs for peptide reconstitution. Bacteriostatic water is the standard solvent referenced in published peptide handling protocols for in vitro preparations; Nexyra Lab supplies Bacteriostatic Water (BAC Water) for this purpose. Storage, aliquoting, and concentration verification should be performed in accordance with institutional biosafety and quality-assurance guidelines.

Conclusion

Ipamorelin and CJC-1295 No DAC represent two mechanistically distinct tools for investigating GH secretagogue biology in preclinical and in vitro contexts. Ipamorelin's GHS-R1a selectivity and extended half-life relative to the No DAC variant make it a precise instrument for ghrelin-receptor pathway research; CJC-1295 No DAC's pulsatile GHRHR activation profile provides a complementary window into cAMP-driven somatotroph physiology. Used within properly controlled experimental designs, these two research-grade peptides enable investigators to resolve mechanistic questions that neither compound can address in isolation.

Researchers planning literature reviews around these compounds are encouraged to consult the Ipamorelin — Evidence Dossier and the CJC-1295 — Evidence Dossier for a curated overview of the primary literature.

Research Disclaimer

All Nexyra Lab products are for in vitro research and laboratory use by qualified researchers only. They are not approved by the MHRA, FDA, EMA, or any regulatory authority for human or veterinary use. This article summarises published scientific literature for research planning purposes only and does not constitute medical advice.